Back to Journals » OncoTargets and Therapy » Volume 12

Evaluating tisagenlecleucel and its potential in the treatment of relapsed or refractory diffuse large B cell lymphoma: evidence to date

Authors Zavras PD, Wang Y, Gandhi A, Lontos K, Delgoffe GM

Received 20 February 2019

Accepted for publication 29 April 2019

Published 11 June 2019 Volume 2019:12 Pages 4543—4554


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Ms Aruna Narula

Peer reviewer comments 2

Editor who approved publication: Dr Leo Jen-Liang Su

PD Zavras,1 Y Wang,2,3 A Gandhi,4 K Lontos,2,5 GM Delgoffe2,6

1Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2Tumor Microenvironment Center, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA; 3School of Medicine, Tsinghua University, Beijing, People’s Republic of China; 4Blood and Marrow Transplant Program, Department of Medicine, Stanford University, Stanford, CA, USA; 5Division of Hematology/Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA; 6Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA

Abstract: Chimeric antigen receptor (CAR) T cells have changed the treatment landscape of relapsed or refractory diffuse large B cell lymphoma. This review focuses on the biology of tisagenlecleucel and the clinical data that support its use in this setting. In addition, we discuss how it compares to other CAR T products, the financial implications for payers, and ongoing trials.

Keywords: CAR T, tisagenlecleucel, diffuse large B cell lymphoma, DLBCL, refractory DLBCL, lymphoma

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]